BioLife Solutions, Inc.
BLFS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $82 | $143 | $76 | $119 |
| % Growth | -42.6% | 87.9% | -36% | – |
| Cost of Goods Sold | $29 | $97 | $108 | $81 |
| Gross Profit | $54 | $47 | $54 | $38 |
| % Margin | 65.3% | 32.6% | 70.6% | 31.7% |
| R&D Expenses | $8 | $19 | $15 | $12 |
| G&A Expenses | $41 | $56 | $48 | $34 |
| SG&A Expenses | $50 | $80 | $69 | $48 |
| Sales & Mktg Exp. | $10 | $13 | $12 | $14 |
| Other Operating Expenses | $3 | $18 | $10 | $8 |
| Operating Expenses | $61 | $118 | $94 | $68 |
| Operating Income | -$7 | -$71 | -$6 | -$35 |
| % Margin | -8.7% | -49.4% | -7.8% | -29.5% |
| Other Income/Exp. Net | -$4 | $5 | $1 | $6 |
| Pre-Tax Income | -$11 | -$66 | -$5 | -$29 |
| Tax Expense | -$0 | $0 | -$5 | -$20 |
| Net Income | -$20 | -$66 | -$140 | -$9 |
| % Margin | -24.5% | -46.4% | -183.4% | -7.5% |
| EPS | -0.44 | -1.52 | -3.29 | -0.23 |
| % Growth | 71.1% | 53.8% | -1,330.4% | – |
| EPS Diluted | -0.44 | -1.52 | -3.29 | -0.23 |
| Weighted Avg Shares Out | 46 | 44 | 42 | 39 |
| Weighted Avg Shares Out Dil | 46 | 44 | 42 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $2 | $1 | $0 |
| Depreciation & Amortization | $9 | $12 | $20 | $13 |
| EBITDA | $2 | -$45 | -$124 | -$17 |
| % Margin | 1.9% | -31.6% | -162.9% | -14% |